HHS Puts $4 Million Toward Faster Syphilis Testing

The U.S. Department of Health and Human Services said August 12 that it is directing $4 million toward rapid, point-of-care syphilis testing. About $3.25 million will go to state and local health departments already funded through a CDC cooperative agreement for STD prevention. The remaining money will support national partners providing implementation and technical assistance.

The program targets emergency departments, maternal and child health programs, correctional intake, substance use treatment programs, and other settings that can reach people outside routine clinical care. Awards are scheduled to support testing and links to care from August 2026 through February 2027.

The case numbers behind the grant

HHS reported nearly 4,000 congenital syphilis cases in 2024, close to a 700 percent increase over the prior decade. In 2023, congenital syphilis contributed to 279 stillbirths and infant deaths. The agency estimated that 83 percent of that year's cases could have been prevented with timely testing and treatment, while more than 40 percent of pregnant women whose babies were affected were not tested in time to receive adequate treatment before delivery.

Those figures explain the focus on speed and setting. A result available during the same encounter may help when someone is unlikely to return for another appointment. The grant is betting that moving testing closer to where people already receive services can close part of that gap.

Rapid testing is not the whole diagnostic process

CDC's 2024 laboratory recommendations describe syphilis diagnosis as a combination of treponemal and nontreponemal antibody tests. RPR is one common nontreponemal test. A single reactive serology result can misclassify a person's status, so laboratories use testing algorithms to distinguish untreated infection from a past treated infection and other patterns.

CDC also notes that an accurate point-of-care antibody test can shorten the time from testing to treatment because the infection may be identified during the visit. That is the practical advantage HHS is trying to expand. It does not mean every rapid result is a complete diagnosis or that follow-up testing and clinical interpretation disappear.

Lab Test Superstore's syphilis test page explains the standard blood-testing process and result limits. LTS has also covered the World Health Organization's first global database tracking STI rates, which addresses surveillance rather than individual diagnosis.

What the announcement cannot tell us yet

A funding notice is not an outcome study. HHS did not report which jurisdictions received each award, how many tests will be performed, or what share of people with reactive results will complete treatment. The release also does not change existing screening recommendations or expand who is advised to test.

The measurable question comes next: whether local programs can turn same-visit testing into earlier diagnosis and completed care. The agency's own numbers show why that is worth testing, but the grant's effect will depend on execution over the next several months.

This article is editorial commentary and is not medical advice. It has not been reviewed by a physician and should not be used to make decisions about syphilis diagnosis, pregnancy care, treatment, or testing frequency.